FDA Peptide Regulation and HHS Policy Holt Law Major peptide regulatory news this week. The FDA announced on April 15 that it will remove 12 peptides from Category 2 of the 503A bulk drug substances list after seven calendar days. BREAKING: The FDA just reversed their 2023 peptide ban. 12 peptides pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu 5. MOTS C 6. The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of When will the FDA reclassify BPC 157 to Category 1 Octagon AI